Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires 9,289 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani bought 9,289 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $2.15 per share, with a total value of $19,971.35. Following the completion of the purchase, the chief financial officer now owns 44,500 shares in the company, valued at approximately $95,675. This represents a 26.38 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Anixa Biosciences Stock Up 7.0 %

Shares of ANIX traded up $0.15 on Wednesday, reaching $2.28. The stock had a trading volume of 304,271 shares, compared to its average volume of 100,660. The firm has a market capitalization of $73.37 million, a PE ratio of -5.85 and a beta of 0.82. The firm has a 50-day moving average of $2.86 and a 200 day moving average of $3.03. Anixa Biosciences, Inc. has a twelve month low of $2.07 and a twelve month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, sell-side analysts anticipate that Anixa Biosciences, Inc. will post -0.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIX has been the subject of a number of analyst reports. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Westside Investment Management Inc. grew its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the period. Virtu Financial LLC acquired a new stake in Anixa Biosciences during the 3rd quarter valued at $34,000. Tyler Stone Wealth Management grew its holdings in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the last quarter. International Assets Investment Management LLC grew its holdings in Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the last quarter. Finally, Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the 2nd quarter valued at $31,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.